# Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

> **NCT02000817** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 30 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** Otelixizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02000817
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-12
- **Primary completion:** 2018-09-27
- **Final completion:** 2018-09-27
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02000817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02000817, "Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02000817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*